Intrathecal Administration of Autologous Mesenchymal Stem Cell-derived Neural Progenitors (MSC-NP) in Patients With Multiple Sclerosis
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01933802|
Recruitment Status : Completed
First Posted : September 2, 2013
Last Update Posted : March 19, 2018
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
|Condition or disease||Intervention/treatment||Phase|
|Multiple Sclerosis||Biological: intrathecal administration of autologous MSC-NP||Phase 1|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||20 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Phase 1 Safety Study of Autologous Bone Marrow-derived Mesenchymal Stem Cell-derived Neural Progenitor Cells (MSC-NP), Expanded Ex Vivo, Administered Intrathecally in Patients With Multiple Sclerosis|
|Study Start Date :||April 2014|
|Actual Primary Completion Date :||December 2016|
|Actual Study Completion Date :||March 2017|
Experimental: autologous MSC-NP
intrathecal administration of autologous MSC-NP in three doses at three month intervals
Biological: intrathecal administration of autologous MSC-NP
Autologous MSC-NPs administered intrathecally at a dose between 2 and 10 million cells, depending on ex vivo expansion characteristics. Three doses will be administered at 3 month intervals.
- Number of participants with adverse events [ Time Frame: 9 months ]The primary objective of the study is to assess the safety and tolerability of intrathecal therapy with autologous MSCNPs in MS. Number of participants with adverse events will be documented 1 day, 1 week, 1 month and 2 months post treatment for three treatments (followup for third treatment is 3 months instead of 2 months).
- Number of participants with adverse events . [ Time Frame: 30 months ]The co-primary objective will be to observe long term safety of the treatment 6 months and 30 months following the last treatment.
- Preliminary evaluation of efficacy [ Time Frame: 9 months ]The secondary objective is to observe trends in efficacy over the course of the experimental treatment. Outcome measures include evoked potentials (baseline and 3 months post 3rd dose) ,quality of life questionnaire, EDSS, and MSFC (baseline, at the time of each dose, and 3 and 6 months after third dose), and MRI (baseline, 2 months after first dose, and 3 and 24 months after third dose).
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years to 70 Years (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
- Diagnosis of MS as defined by the McDonald criteria
- Diagnosis of primary progressive or secondary progressive MS
- Between the ages of 18-70 years
- Significant disability shown by an Expanded Disability Status Score (EDSS) of 3.0 or greater that was not acquired within the last 12 months
- Stable disease state as evidenced by a lack of gadolinium-enhancing lesions on an MRI and by a stable MRI disease burden (number of T2 lesions and size of lesions) in the last six months and no significant change in EDSS (1 point or more) in the last 12 months
- Must agree to undergo MRIs at the time of enrollment, 2 months after the first treatment, and 27 months after the last treatment
- Live in northern New Jersey, southern New York, or southwestern Connecticut during the study period, or patients must be able to arrange reliable travel accommodations to be present for every study visit if they live farther away.
- Pregnant or nursing mothers or any woman intending to become pregnant in the next three years
- All patients will have pre-study liver function tests, PT/PPT, platelets, hematocrit, and renal function laboratory tests done. Only patients whose values are in the normal range as determined by the laboratory norms based on age and sex will be allowed to participate.
- Use of systemic chemotherapeutic or anti-mitotic medications within three months of study start date due to the possibility of interference with bone marrow procedure
- Any patients with a history of or with active malignancy
- Use of steroids within three months of the study start date, as this would suggest a highly active disease state
- History of cirrhosis due to increased risk of central nervous system (CNS) infection
- Poorly controlled hypertension because of increased risk for stroke or CNS hemorrhage. Specifically, any patient with a systolic blood pressure value of ≥ 145 mm/Hg or a diastolic blood pressure value of ≥ 95 mm/Hg will be excluded from study participation.
- History of thyroid disorders or other endocrine disorders because of hormone influence on cell growth
- History of central nervous system infection or immunodeficiency syndromes due to increased risk of CNS infection
- Preexisting blood disease (such as bone marrow hypoplasia, leukopenia, thrombocytopenia, or significant anemia) due to invasive nature of bone-marrow aspiration
- Previous or current history of a coagulation disorder
- Any metal in the body, which is contraindicated for MRI studies
- Allergy to any of the antibiotics used in this study, e.g. tobramycin, vancomycin, or gentamicin
- Patients with alcohol or other substance abuse problems
- Other major disease that, in the opinion of the Principal Investigator, would preclude participation in the study
- Patients with HBV, HCV, syphilis, HIV-1, or HIV-2.
- Any evidence of significant cognitive dysfunction based on a screening history and physical examination because it would preclude giving a truly informed consent
- Patients who are enrolled in another clinical trial for MS treatment or who have received any study drug/biologics within the last 6 months
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01933802
|United States, New York|
|Tisch MS Research Center of New York|
|New York, New York, United States, 10019|
|Principal Investigator:||Saud A Sadiq, MD||Tisch MS Research Center of New York|
Publications of Results:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
|Responsible Party:||Tisch Multiple Sclerosis Research Center of New York|
|Other Study ID Numbers:||
IND 13889 ( Other Identifier: FDA )
|First Posted:||September 2, 2013 Key Record Dates|
|Last Update Posted:||March 19, 2018|
|Last Verified:||March 2018|
mesenchymal stem cells
Demyelinating Autoimmune Diseases, CNS
Autoimmune Diseases of the Nervous System
Nervous System Diseases
Immune System Diseases